Business context and reporting period
cbdMD, Inc. reported on November 4, 2026, that its wholly owned subsidiary To Be Brands, LLC completed its acquisition of specified Twinlab Consolidated Holdings, Inc. business assets on October 30, 2026, following approval by a Florida court. This is a transaction filing, not a report of periodic operating results.
The acquired business markets and sells nutritional supplements and natural products, including vitamins, minerals, sports nutrition, skincare, herbal teas, and products under brands such as Twinlab, Reserveage, ResVitale, Metabolife, and Alvita. Acquired assets include intellectual property, contracts, inventory, accounts receivable, goodwill, and interests in four subsidiaries. cbdMD said the acquisition is intended to diversify its business beyond CBD and expand its product categories.
Transaction and key financial terms
- Debt: The acquisition subsidiary and acquired subsidiaries issued a $1.75 million senior secured promissory note to the secured creditor. It bears 9% annual interest, matures two years after closing, and is secured by the acquired assets.
- Equity consideration: cbdMD issued 2,229,805 common shares, valued in the agreement at $1.00 per share and representing 19.9% of shares outstanding when the purchase agreement was executed.
- Additional shares: The company agreed to issue 132,730 additional shares to maintain the agreement’s target percentage, subject to shareholder approval under NYSE American rules. It will use commercially reasonable efforts to seek approval within 270 days after closing.
- Other consideration: The buyer assumed specified liabilities and the senior secured debt; the filing says the balance of the assignors’ obligations to the secured creditor was forgiven but does not state its amount.
The issued and potential additional shares are subject to leak-out restrictions. cbdMD agreed to file a resale registration statement within nine months after closing. The shares were issued, or if issued will be issued, in reliance on registration exemptions.
Financial results and material changes
The filing does not provide acquired-business revenue, profit, cash flow, margins, or other operating results, nor does it quantify the acquisition’s impact on cbdMD’s financial statements. It also does not provide a clear value for the assumed liabilities beyond the $1.75 million note. Audited and interim financial statements for the acquired business and required pro forma financial information are to be filed by amendment within 71 calendar days after the filing deadline.
The material change disclosed is cbdMD’s acquisition of the Twinlab-related assets and subsidiaries, financed partly through secured debt and a substantial equity issuance. The filing contains no comparable-period financial data.
Outlook, risks, and contingencies
Management characterized the acquisition as a strategic diversification opportunity; the filing gives no financial guidance, forecast, or quantified expected benefits. Twinlab and the assignors will provide specified transition services, including information technology, accounting, and human resources support. cbdMD also agreed to offer service agreements to certain employees who wish to continue providing services.
Key matters include the secured note and its 9% interest cost, the creditor’s security interest in acquired assets, shareholder approval required for the additional shares, resale restrictions and registration obligations, and the integration and transition of the acquired business. The filing describes the transaction as a court-approved private sale and states that acquired assets are subject to permitted encumbrances and exclusions under the purchase agreement.
Important facts for investors to verify
- Review the forthcoming acquired-business financial statements and pro forma information when filed, including revenue, profitability, cash flow, and purchase-accounting effects.
- Confirm the total liabilities assumed and the amount of the assignors’ obligations forgiven, which are not quantified in this filing.
- Track shareholder approval and issuance of the 132,730 additional shares, as well as the resale registration and leak-out terms.
- Review the full promissory note, security agreement, purchase agreement, and transition services agreement for covenants, remedies, excluded assets, and other detailed terms.
- Assess post-closing integration, transition-service needs, and whether the acquired brands and operations deliver the diversification benefits management described.